quinagolide has been researched along with Substance-Withdrawal-Syndrome* in 3 studies
3 other study(ies) available for quinagolide and Substance-Withdrawal-Syndrome
| Article | Year |
|---|---|
Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma.
Topics: Aminoquinolines; Dopamine Agonists; Female; Humans; Middle Aged; Prolactinoma; Substance Withdrawal Syndrome | 2014 |
Prolactinoma-associated headache and dopamine agonist treatment.
The aim of this article is to investigate the phenotype and etiology of prolactinoma-associated headache as well as present and discuss the plausible pain-relieving effect of dopamine agonist treatment.. In this case-based audit we included 11 patients with prolactinomas and one patient with idiopathic hyperprolactinemia presenting with headache that subsequently improved or resolved after dopamine agonist treatment.. A significant ipsilateral location of tumor mass and reported headache symptoms was observed (p = 0.018). After dopamine agonist treatment seven out of 12 patients became pain free within 2.5 months; after one year of treatment 11 out of 12 reported headache improvement or resolution. Average tumor volume reduction after treatment was 47 ± 22% during 9.5 ± 8.4 months of follow-up. There was no significant association between headache relief and tumor shrinkage (p = 0.43) or normalization of serum prolactin (p = 1.00), respectively.. 1) The significant association between lateralization of tumor and headache suggests a mechanical origin of the headache, 2) headache responded to dopamine agonist treatment in most patients, and 3) our observations encourage future prospective controlled trials to investigate the role of hyperprolactinemia in the pathogenesis of headache as well as the therapeutic effects of dopamine agonists. Topics: Adult; Aminoquinolines; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Headache; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Recurrence; Substance Withdrawal Syndrome | 2014 |
Benign intracranial hypertension associated with the withdrawal of a non-ergot dopamine agonist.
The cases are reported of two patients who developed benign intracranial hypertension after the withdrawal of the novel non-ergot derived dopamine agonist CV 205 502 (quinagolide). Topics: Adult; Aminoquinolines; Cerebrovascular Circulation; Dopamine Agents; Female; Humans; Hyperprolactinemia; Migraine Disorders; Pseudotumor Cerebri; Substance Withdrawal Syndrome | 1994 |